The FDA has granted Breakthrough Device designation to MeMed BV Flex, a blood test that differentiates between types of ...

A painless new method of conducting blood tests in people with learning disabilities is currently being trialled by the ...

MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute ...

The company's BV Flex test measures patient immune proteins in capillary blood samples to determine whether an individual has a bacterial or viral infection.

Background Blood biomarkers exhibit promising potential for monitoring brain injuries. Nevertheless, there exists a dearth of understanding concerning the influence of various impact characteristics ...

A new needle-free blood test, TAP, launched by UHMBT NHS Trust, transforms care for patients with learning disabilities or needle phobia ...